177 related articles for article (PubMed ID: 30983508)
1.
Petry N; Lupu R; Gohar A; Larson EA; Peterson C; Williams V; Zhao J; Wilke RA; Hines LJ
Pharmacogenomics; 2019 Apr; 20(5):343-351. PubMed ID: 30983508
[No Abstract] [Full Text] [Related]
2. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
3. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
Kumar Y; Kung S; Shinozaki G
J Psychopharmacol; 2014 Dec; 28(12):1143-8. PubMed ID: 25122046
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
[TBL] [Abstract][Full Text] [Related]
5. Considerations on safety concerns about citalopram prescribing.
Sheeler RD; Ackerman MJ; Richelson E; Nelson TK; Staab JP; Tangalos EG; Dieser LM; Cunningham JL
Mayo Clin Proc; 2012 Nov; 87(11):1042-5. PubMed ID: 23018033
[No Abstract] [Full Text] [Related]
6. A comparative study of QT prolongation with serotonin reuptake inhibitors.
Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
[TBL] [Abstract][Full Text] [Related]
7. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
8. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.
Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Koller D; Talegón M; Ovejero-Benito MC; López-Rodríguez R; Cabaleiro T; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):501-511. PubMed ID: 29136336
[TBL] [Abstract][Full Text] [Related]
9. The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Hussaarts KGAM; Berger FA; Binkhorst L; Oomen-de Hoop E; van Leeuwen RWF; van Alphen RJ; Mathijssen-van Stein D; de Groot NMS; Mathijssen RHJ; van Gelder T
Pharm Res; 2019 Dec; 37(1):7. PubMed ID: 31845095
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
11. [Citalopram is not safe from the cardiac point of view--SSRI preparations can cause prolonged QTc time].
Odar-Cederlöf I; Hjelmström P; Jersenius I; Andersson M; Rasmanis G; Bergman U
Lakartidningen; 2006 Apr 5-11; 103(14):1112-4. PubMed ID: 16681095
[No Abstract] [Full Text] [Related]
12. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
Chang M; Tybring G; Dahl ML; Lindh JD
Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
[TBL] [Abstract][Full Text] [Related]
13. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the risk of QT prolongation among SSRIs.
Funk KA; Bostwick JR
Ann Pharmacother; 2013 Oct; 47(10):1330-41. PubMed ID: 24259697
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients.
Bråten LS; Haslemo T; Jukic MM; Ingelman-Sundberg M; Molden E; Kringen MK
Neuropsychopharmacology; 2020 Feb; 45(3):570-576. PubMed ID: 31649299
[TBL] [Abstract][Full Text] [Related]
17. Prescribe escitalopram instead of citalopram.
Keller DL
Am J Med; 2013 Jun; 126(6):e21. PubMed ID: 23684405
[No Abstract] [Full Text] [Related]
18. Citalopram (Celexa) and QT interval prolongation.
Med Lett Drugs Ther; 2012 Sep; 54(1398):71-2. PubMed ID: 22992488
[No Abstract] [Full Text] [Related]
19. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?
Vieweg WV; Hasnain M; Howland RH; Hettema JM; Kogut C; Wood MA; Pandurangi AK
Am J Med; 2012 Sep; 125(9):859-68. PubMed ID: 22748401
[TBL] [Abstract][Full Text] [Related]
20. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
